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Abbreviations
AGP: alpha-1-acid glycoprotein, CRP: c-reactive protein, 
EDTA: ethelenediametelenetatraacetic acid, FBC: full blood 
count, G6PD: glucose-6-phosphate dehydrogenase, GWAS: 
genome-wide association study, Hb: haemoglobin, IRIDA: 
iron-refractory iron deficiency anaemia, KWLPS: Kiang West 
Longitudinal Population Study; LSHTM: London School of 
Hygiene & Tropical Medicine, MAF: minor allele frequency, 
MRCG: Medical Research Council The Gambia, SNP: single 
nucleotide polymorphism, sTfR: soluble transferrin receptor, 
TMPRSS6: transmembrane protease serine 6, TSAT: transferrin 
saturation, UIBC: unsaturated iron binding capacity, WABR: 
West Africa BioResource, WK: West Kiang
Introduction
Despite aggressive implementation of iron supplementation 
programs, either alone or in combination with food-based 
supplementation, the prevalence of anaemia remains high in 
low- and middle-income countries1,2. The World Health 
Organisation (WHO) has set 2050 as a target date by which the 
current anaemia burden will be reduced by half. In order to 
achieve this goal, it will be important to identify the major 
drivers of anaemia.
The transmembrane protease serine 6 gene (TMPRSS6), which 
encodes for matriptase-2, is one of the negative regulators of 
hepcidin3, the key iron homeostasis regulator4. When serum 
iron levels are low, matripase-2 suppresses hepcidin expression, 
allowing more iron from the diet to be absorbed through the 
intestines into the bloodstream5,6. A single nucleotide poly-
morphism (SNP) in the TMPRSS6 gene can lead to decreased 
expression or inactivation of matripase-27, which would then 
lead to inappropriately elevated hepcidin levels, inhibited iron 
absorption and would thereby result in an increased risk of 
anaemia5.
Multiple SNPs in the TMPRSS6 gene have been linked to 
iron-refractory iron deficiency anaemia (IRIDA), a hereditary 
anaemia that is not responsive to oral iron supplementation8. In 
addition, many SNPs in TMPRSS6 (including rs855791, rs4820268 
and rs3345321) have been linked to an increased risk of iron 
deficiency anaemia (IDA) in genome-wide association studies 
(GWAS)9–11. In Caucasian populations, rs855791 has been 
reported to be in strong linkage disequilibrium (LD) with 
rs4820268 (r2=0.83) and rs2235321 (r2=0.44)12. Similarly, in 
Asian populations, rs855791 is reported to be in high LD with 
rs4820268 (r2=0.65)12. 
The minor allele frequency (MAF) of these SNPs varies between 
racial and ethnic groups. In African populations, the MAF of 
rs855791 is lower (10%) than in East Asians (57%), South 
Asians (54%) and Europeans (39%)13. Similarly, the MAF of 
rs4820268 is lower in Africans (28%) compared to Europe-
ans (42%), whereas, the MAF of rs2235321 in Africans (41%) 
is similar to that of the European population (42%)13. The 
effects of these SNPs (rs855791, rs4820268 and r2235321) 
on iron absorption and hepcidin levels in Subsaharan African 
populations has not been studied.
We hypothesize that the variant alleles at these SNPs may 
impair iron absorption and may be partially responsible for the 
disproportionately high anaemia prevalence in sub-Saharan 
Africa. Here, we propose to investigate effects of these three 
TMPRSS6 SNPs on oral iron absorption in Gambian adults.
We anticipate that this study will provide a biological insight 
into the association of these three TMPRSS6 variants with 
anaemia.
Protocol
Study objectives and outcome measures
The primary objective of this study is to assess the impact of 
single and multiple copies of variant alleles of the TMPRSS6 
SNPs (rs855791, rs4820268 and rs2235321) on oral iron 
absorption. The primary outcome measure will be the change 
in serum iron concentration before and five hours after a single 
400 mg dose of ferrous sulfate iron given orally (Figure 1).
Secondary endpoints related to the primary objective are:
(1)    Increase in transferrin saturation (TSAT) above baseline 
after a single oral 400 mg dose of ferrous sulfate iron.
(2)    Increase in serum unbound iron binding capacity (UIBC) 
above baseline after a single oral 400 mg dose of ferrous sul-
fate iron.
(3)    Increase in serum hepcidin levels above baseline after a 
single oral 400 mg dose of ferrous sulfate iron.
(4)    Ferritin, haemoglobin, mean corpuscular volume (MCV) and 
soluble transferrin receptor (sTFR) at baseline, as measures of 
iron status.
(5)    White blood cell count (WBC), granulocyte count, C-reactive 
protein (CRP) and alpha-1-acid glycoprotein (AGP) at base-
line, as measures of the inflammatory state.
(6)    Sickle cell haemoglobin and glucose 6-phosphatase deficiency 
(G6PD) status at baseline to assess potential confounding 
effects of these two genetic conditions, which are common in 
this population.
Study design
We will employ a recall-by-genotype study design, in which 
participant selection will be based on TMPRSS6 SNPs reported 
to be associated with the risk of iron-deficiency anaemia: 
rs855791, rs4820268 and rs223532110,14,15. We will utilize the 
West African BioResouce (WABR), which contains the Kiang 
West Longitudinal Population Study (KWLPS) as the basis 
for selection of pre-genotyped participants16.
Study site
The proposed study will be conducted within the population 
of West Kiang (WK) District, in the Lower River Region of 
The Gambia, and study procedures will be conducted at the 
Medical Research Council The Gambia (MRCG) at London 
School of Hygiene & Tropical Medicine (LSHTM), Keneba 
Field Station16. Individuals that are eligible for the study 
but have moved to the coastal region of The Gambia will be 
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Figure 1. Time line showing oral iron absorption test.
followed-up by a fieldworker and study procedures will be 
conducted at the MRCG Fajara site. Participants currently residing 
in WK will be prioritised.
Participants
A total of 300 participants (male and female) will be recruited. 
Participants will be chosen based on three TMPRSS6 SNPs 
(rs855791, rs4820268 and rs2235321), from which we will 
generate nine genotype combinations, as detailed in Table 1. This 
will allow the investigation of the effect of each SNP individually 
and in combination. Composite genotype group 3 is the control 
group with no variant alleles. Due to the low MAF of rs855791 
in our study population, we are unable to include homozygotes 
for the variant allele. This limited the selection of genotype 
combinations, and only nine combinations had sufficient 
participants to include in the study.
For inclusion, participants must be 18 years and above, in 
good physical health, have available genotype data, be able 
to fast overnight prior to the study visit and be able to give 
informed consent. Individuals will be excluded from the study 
if they have any signs of infection at the time of enrolment, 
are severely anaemic (Hb <7 g/dl), pregnant or breastfeeding, or 
have a positive malaria test at screening.
Sample size calculation
The total sample size will be 300. This will include approximately 
62 wild type subjects and an average of 31 in each of the eight 
variant genotype groups. This study size will be able to detect 
a 12% mean decrease in serum iron at five hours after oral 
iron supplementation between the wild type and the variant 
genotype groups with 90% power and a type 1 error of 0 in this 
study.
Study procedures
Potential participants with the candidate composite genotypes 
of interest will be selected from the study database by the prin-
cipal investigator, and contact details (including address and 
phone number) will be extracted from the WK Demographic 
Surveillance System16 by the study data manager. Participants will 
be contacted either in person or by telephone. Participants who 
provide informed consent will be invited to the study site where 
the rest of the study procedures will be conducted, as summarised 
in Figure 2.
Each participant will be given a single dose of 400mg ferrous 
sulfate oral iron (2x 200mg ferrous sulfate tablets), equiva-
lent to 130mg elemental iron. To ensure that the iron tablets 
are taken, a nurse will observe and record the time injestion. 
Participants will be asked to stay at the study site until the 
study is completed, which is after collecting the five hour post 
supplementation blood sample (Figure 1).
All data generated from this study will be anonymised by 
allocating a unique study ID to each participant. Screening, 
enrolment and sample collection details will be collected in 
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1 AA/GG/AA A/A G/G A/A 2
2 AG/GG/GA A/G G/G G/A 2
3 GG/GG/AA G/G G/G A/A 0
4 GG/GG/GA G/G G/G A/G 1
5 GG/GG/GG G/G G/G G/G 2
6 AG/AG/AA G/A G/A A/A 2
7 AG/GG/AA G/A G/G A/A 1
8 GG/AG/AA G/G G/A A/A 1
9 GG/AG/GA G/G G/A A/G 2
Figure 2. Flow chart showing the study procedures. WABR = West Africa Bioresource.
standard study forms and entered into the study database. Data 
will be double-entered by two data entry clerks and verified by a 
data supervisor.
In order to prevent bias in treatment, the composite genotype 
of individuals will not be disclosed to the study team (data 
management, field and clinical staff). In addition, participants 
will be recruited in groups at random, and individuals with 
different composite genotype groups will be mixed during study 
visits.
Sample collection
A 3ml whole blood sample will be collected at baseline. 
2.5ml will be collected in lithium heparin tubes. 500µl will be 
collected in EDTA (ethylenediaminetetraacetic acid) micro tubes 
to be used for full blood count (FBC), malaria rapid testing and 
sickle screening.
Post supplementation blood samples (3ml blood sample in 
lithium heparin tube) will be collected at two hours and five 
hours following iron ingestion. Pre- and post-supplementation 
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blood samples in lithium heparin tubes will be spun and the 
plasma aliquoted in barcode-labelled tubes and stored at -20°C for 
iron biomarker analysis.
Laboratory analyses
FBC will be analysed using a 3-part haematology analyser 
(Medonic M-series, Boule Medical, Sweden). Iron biomark-
ers [serum iron, unsaturated iron binding capacity (UIBC), fer-
ritin, soluble transferrin receptor (sTfR), haptoglobin (HP)] and 
inflammatory markers [C-reactive protein (CRP) and alpha-1-acid 
glycoprotein (AGP)] will be measured using a Cobas Integra 
400 plus biochemistry analyser (Roche Diagnostics). Total iron 
binding capacity and transferrin saturation of iron (TSAT) will 
be calculated from serum iron and UIBC. Plasma hepcidin levels 
will be measured using a commercially available ELISA (DRG 
Instruments GmbH, Germany). The sickle rapid test will be 
analysed using the sodium metabisulphide method and posi-
tive samples will be genotyped by Hb electrophoresis. G6PD 
deficiency will be assessed using a qualitative enzyme assay 
(G6PD Hb+ R&D Diagnostics).
Statistical analysis plan
Primary analysis will be to assess the change in serum iron 
between the composite genotype groups at the five hours post- 
supplementation time point. A linear model will be fitted with 
genotype group as the independent variable and serum iron or 
TSAT as response variables and genotype group as the main pre-
dictor, with the inclusion of age, sex and inflammation status 
(CRP and AGP levels) as covariates. Using the same approach, 
we will also examine the effect of genotype on secondary 
outcome measures. The baseline iron level of the participants 
may vary. All secondary analysis are exploratory.
In order to remove this potential source of bias, we will adjust 
for baseline serum iron in the regression analysis. If the missing 
data rate is more than 5%, we will consider imputation. The 
follow-up duration is short; thus, we expect little bias from loss 
to follow-up. We will also consider sensitivity analysis, fitting 
a multivariate regression model where the main outcomes of 
interest (including TSAT, iron and hepcidin) will be jointly 
regressed to the same set of predictors.
Ethical statement
This study has been approved by the MRC Unit The Gambia at 
the LSHTM Scientific Coordinating Committee, MRC Unit 
The Gambia at the LSHTM / Gambia Government Joint Ethics 
Committee (SCC1429), and the LSHTM Ethics Committee 
(LSHTM Ethics reference number 11679). A trained field 
worker will visit each potential study participant to issue an 
information sheet detailing the purpose and nature of the 
study (see Extended data)17. Individuals who cannot read will 
have the information sheet translated into a language they 
understand by the fieldworker, in presence of an independent 
witness. Furthermore, participants will be given the opportunity 
to ask questions to the investigators that they deem important. 
Participants will be informed that they are free to withdraw 
from the study anytime, and they can further raise any question 
about the study with the investigators.
Participants will provide written informed consent, and those who 
cannot write will provide a thumbprint prior to enrolling into the 
study. Confidentiality of study participants will be protected by 
anonymising all study samples and forms by allocating a study 
number to each participant.
This study was retrospectively registered with ClinicalTrials.gov 
(NCT03341338) on 14th November 2017.
Dissemination of information
The study results will be published in relevant peer-reviewed 
journals and key findings will be presented at international 
scientific meetings. Data sharing will be in agreement with the 
MRC policy on research data sharing.
Study status
The study is in the data collection phase at the time of publication.
Discussion
GWAS has identified several genetic variants associated with iron 
status3,11,15,18–20. However, detailed understanding of genotype- 
phenotype relationships is required to identify their effects on 
iron absorption. The recall-by-genotype (RbG) study design 
is an efficient tool for detailed investigations of genotype- 
phenotype relationships because it minimizes confounders 
and improves statistical power while reducing sample size21. 
In this study, we will use the RbG study design to assess the 
functional effects of the three common TMPRSS6 variants on iron 
absorption. We expect that this study will provide new insights 
into the association between these TMPRSS6 gene variants and 




No underlying data are associated with this article
Extended data
Figshare: Jallow et al. Patient Information sheet and consent 
form.docx. https://doi.org/10.6084/m9.figshare.8058959.v217 
Data are available under the terms of the Creative Commons 
Zero “No rights reserved” data waiver (CC0 1.0 Public domain 
dedication).
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